Zhongchao Inc. (ZCMD): Price and Financial Metrics

Zhongchao Inc. (ZCMD): $1.11

0.00 (0.05%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

C

Add ZCMD to Watchlist
Sign Up

Industry: Medical - Services

Industry

NR

Ranked

#46 of 83

in industry

ZCMD Price/Volume Stats

Current price $1.11 52-week high $1.40
Prev. close $1.11 52-week low $0.60
Day low $1.11 Volume 100
Day high $1.11 Avg. volume 22,958
50-day MA $1.15 Dividend yield N/A
200-day MA $1.16 Market Cap 21.29M

ZCMD Stock Price Chart Interactive Chart >

ZCMD Stock Summary

  • With a price/sales ratio of 18.49, ZHONGCHAO INC has a higher such ratio than 94.3% of stocks in our set.
  • With a year-over-year growth in debt of 2,638.86%, ZHONGCHAO INC's debt growth rate surpasses 99.45% of about US stocks.
  • In terms of volatility of its share price, ZCMD is more volatile than merely 7.75% of stocks we're observing.
  • Stocks that are quantitatively similar to ZCMD, based on their financial statements, market capitalization, and price volatility, are FTFT, GROW, CCF, PEGY, and CASH.
  • ZCMD's SEC filings can be seen here. And to visit ZHONGCHAO INC's official web site, go to www.izcmd.com.

ZCMD Valuation Summary

  • In comparison to the median Healthcare stock, ZCMD's EV/EBIT ratio is 913.79% lower, now standing at -94.4.
  • ZCMD's price/earnings ratio has moved down 122.3 over the prior 44 months.

Below are key valuation metrics over time for ZCMD.

Stock Date P/S P/B P/E EV/EBIT
ZCMD 2023-09-22 18.5 8.7 -89.0 -94.4
ZCMD 2023-09-21 18.3 8.7 -88.2 -93.5
ZCMD 2023-09-20 18.2 8.6 -87.4 -92.7
ZCMD 2023-09-19 18.5 8.7 -89.0 -94.4
ZCMD 2023-09-18 17.7 8.4 -85.0 -90.0
ZCMD 2023-09-15 18.0 8.5 -86.6 -91.8

ZCMD's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ZCMD has a Quality Grade of C, ranking ahead of 45.59% of graded US stocks.
  • ZCMD's asset turnover comes in at 0.685 -- ranking 24th of 51 Personal Services stocks.
  • 500 - Internal server error

The table below shows ZCMD's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2020-12-31 0.685 0.660 0.409
2020-12-31 0.685 0.660 0.409
2019-12-31 0.937 0.687 0.772

Zhongchao Inc. (ZCMD) Company Bio


Zhongchao, Inc. is a holding company that engages in the provision of healthcare information, education, and training services. It offers online and onsite health information services, healthcare education programs, and healthcare training products, consisting primarily of clinical practice training, open classes of medical topics, interactive case studies, academic conference & workshops, continuing education courses, articles & short videos with educational healthcare content to healthcare professionals as well as the public. The company was founded by Wei Guang Yang on April 16, 2019 and is headquartered in Shanghai, China.


ZCMD Latest News Stream


Event/Time News Detail
Loading, please wait...

ZCMD Latest Social Stream


Loading social stream, please wait...

View Full ZCMD Social Stream

Latest ZCMD News From Around the Web

Below are the latest news stories about ZHONGCHAO INC that investors may wish to consider to help them evaluate ZCMD as an investment opportunity.

Zhongchao Inc. Announces Serving over 10,000 Breast Cancer Patients with Its Comprehensive Disease Management

Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services for patients with cancer and other major diseases, today announced it has achieved a milestone of serving over 10,000 breast cancer patients in China with comprehensive disease management services since 2021. By offering disease management services, Zhongchao aims to ensure effective medical treatments while reducing financial hardships and enhance the overall quality of l

Yahoo | August 24, 2023

Zhongchao Inc. Partners with Ximalaya to Launch the First Audio Course Series for Cancer Education

Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services for patients with cancer and other major diseases, today announced that it cooperates with Shanghai Ximalaya Technology Co., Ltd. ("Ximalaya"), a widely popular Chinese online audio sharing platform in China, to launch the first series of audio courses dedicated to cancer education.

Yahoo | July 11, 2023

Zhongchao Inc. Launch Digital Online Education Platform for Common Diseases Clinical Diagnosis and Treatment

Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services for patients with cancer and other major diseases, today announced the launch of the Digital Online Education Platform for Common Diseases Clinical Diagnosis and Treatment (the "Platform"). This Platform is designed to elevate the clinical decision-making acumen and patient service capabilities of healthcare professionals, thereby delivering optimal solutions for clinical

Yahoo | June 12, 2023

Zhongchao Inc. Announces Strategic Cooperation with Ximalaya

Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services for patients with cancer and other major diseases, today announced that Beijing Zhongchao Boya Medical Technology Co., Ltd. ("Boya Medical"), one of the Chinese operating entities of which the Company consolidates the financial results with through certain contractual arrangements, has signed a strategic cooperation agreement with Shanghai Ximalaya Technology Co., Ltd. ("X

Yahoo | May 12, 2023

Zhongchao Inc. Announces Naiditawei® Enrolled as a Listed Online Procurement Drug in Ten Provinces(Districts, Cities) in China

Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services for patients with cancer and other major diseases, today announced that Chongqing Xinjiang Pharmaceutical Co., Ltd. ("Xinjiang Pharmaceutical"), one of the Chinese operating entities of which the Company consolidates the financial results with through certain contractual arrangements, successfully integrated its introduced drug Naiditawei® into the procurement scope of med

Yahoo | May 8, 2023

Read More 'ZCMD' Stories Here

ZCMD Price Returns

1-mo N/A
3-mo -4.72%
6-mo N/A
1-year -7.50%
3-year -34.71%
5-year N/A
YTD -3.36%
2022 -35.47%
2021 4.71%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!